New Therapies for Allergic Rhinitis

被引：33

作者：

Braido, Fulvio ^{[1
]}

Sclifo, Francesca ^{[1
]}

Ferrando, Matteo ^{[1
]}

Canonica, Giorgio Walter ^{[1
]}

机构：

[1] Univ Genoa, IRCCS AOU San Martino IST, Allergy & Resp Dis Clin DIMI, I-16132 Genoa, Italy

来源：

CURRENT ALLERGY AND ASTHMA REPORTS | 2014年 / 14卷 / 04期

关键词：

Allergic rhinitis; Therapy; Drugs; Symptoms; Quality of life; Immunology; Inflammation; CETIRIZINE; 10; MG; RANDOMIZED CONTROLLED-TRIAL; CRTH2 ANTAGONIST OC000459; BILASTINE; 20; DOUBLE-BLIND; GRASS-POLLEN; FLUTICASONE PROPIONATE; INTRANASAL CICLESONIDE; RECEPTOR ANTAGONIST; SUPLATAST TOSILATE;

D O I：

10.1007/s11882-014-0422-z

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

Because of its burden on patient's lives and its impact on asthma, allergic rhinitis must be treated properly with more effective and safer treatments. According to guidelines by Allergic Rhinitis and Its Impact on Asthma (ARIA), the classification, pathogenesis, and treatment of allergic rhinitis are well defined. Currently, second-generation antihistamines and inhaled steroids are considered the cornerstone of first-line therapy. However, new formulations of available drugs (e. g., loratadine and rupatadine oral solution, ebastine fast-dissolving tablets, and the combination of intranasal fluticasone propionate and azelastine hydrochloride), recently discovered molecules (e. g., ciclesonide, bilastine, and phosphodiesterase-4 inhibitors), immunologic targets (e. g., omalizumab), and unconventional treatments (e. g., homeopathic treatments) are currently under investigation and represent a new frontier in modern medicine and in allergic rhinitis management. The aim of this review is to provide an update on allergic rhinitis treatment, paying particular attention to clinical trials published within the past 20 months that assessed the efficacy and safety of new formulations of available drugs or new molecules.

引用

页数：8

共 95 条

[1] Topical treatment with aqueous solutions of rofleponide palmitate and budesonide in a pollen-season model of allergic rhinitis [J].

Ahlström-Emanuelsson, C ;

Andersson, M ;

Persson, C ;

Schrewelius, C ;

Greiff, L .

CLINICAL AND EXPERIMENTAL ALLERGY, 2004, 34 (05) :731-735

[2] Allergic rhinitis, rhinosinusitis, and asthma: one airway disease [J].

Bachert, C ;

Vignola, AM ;

Gevaert, P ;

Leynaert, B ;

Van Cauwenberge, P ;

Bousquet, J .

IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 2004, 24 (01) :19-+

[3] Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients [J].

Bachert, C. ;

Kuna, P. ;

Sanquer, F. ;

Ivan, P. ;

Dimitrov, V. ;

Gorina, M. M. ;

van de Heyning, P. ;

Loureiro, A. .

ALLERGY, 2009, 64 (01) :158-165

[4] The effects of a TRPV1 antagonist, SB-705498, in the treatment of seasonal allergic rhinitis [J].

Bareille, Philippe ;

Murdoch, Robert D. ;

Denyer, Jane ;

Bentley, Jane ;

Smart, Kevin ;

Yarnall, Katy ;

Zieglmayer, Petra ;

Zieglmayer, Rene ;

Lemell, Patrick ;

Horak, Friedrich .

INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2013, 51 (07) :576-584

[5] A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma [J].

Barnes, N. ;

Pavord, I. ;

Chuchalin, A. ;

Bell, J. ;

Hunter, M. ;

Lewis, T. ;

Parker, D. ;

Payton, M. ;

Collins, L. Pearce ;

Pettipher, R. ;

Steiner, J. ;

Perkins, C. M. .

CLINICAL AND EXPERIMENTAL ALLERGY, 2012, 42 (01) :38-48

[6] Effect of β-agonists on inflammation cells [J].

Barnes, PJ .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1999, 104 (02) :S10-S17

[7] Liposomes: a new non-pharmacological therapy concept for seasonal-allergic-rhinoconjunctivitis [J].

Boehm, M. ;

Avgitidou, G. ;

El Hassan, E. ;

Moesges, R. .

EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2012, 269 (02) :495-502

[8] Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and AllerGen) [J].

Bousquet, J. ;

Khaltaev, N. ;

Cruz, A. A. ;

Denburg, J. ;

Fokkens, W. J. ;

Togias, A. ;

Zuberbier, T. ;

Baena-Cagnani, C. E. ;

Canonica, G. W. ;

van Weel, C. ;

Agache, I. ;

Ait-Khaled, N. ;

Bachert, C. ;

Blaiss, M. S. ;

Bonini, S. ;

Boulet, L. -P. ;

Bousquet, P. -J. ;

Camargos, P. ;

Carlsen, K. -H. ;

Chen, Y. ;

Custovic, A. ;

Dahl, R. ;

Demoly, P. ;

Douagui, H. ;

Durham, S. R. ;

van Wijk, R. Gerth ;

Kalayci, O. ;

Kaliner, M. A. ;

Kim, Y. -Y. ;

Kowalski, M. L. ;

Kuna, P. ;

Le, L. T. T. ;

Lemiere, C. ;

Li, J. ;

Lockey, R. F. ;

Mavale-Manuel, S. ;

Meltzer, E. O. ;

Mohammad, Y. ;

Mullol, J. ;

Naclerio, R. ;

Hehir, R. E. O. ;

Ohta, K. ;

Ouedraogo, S. ;

Palkonen, S. ;

Papadopoulos, N. ;

Passalacqua, G. ;

Pawankar, R. ;

Popov, T. A. ;

Rabe, K. F. ;

Rosado-Pinto, J. .

ALLERGY, 2008, 63 :8-+

[9] Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 Revision [J].

Brozek, Jan L. ;

Bousquet, Jean ;

Baena-Cagnani, Carlos E. ;

Bonini, Sergio ;

Canonica, G. Walter ;

Casale, Thomas B. ;

van Wijk, Roy Gerth ;

Ohta, Ken ;

Zuberbier, Torsten ;

Schuenemann, Holger J. .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2010, 126 (03) :466-476

[10] GA2LEN skin test study II: clinical relevance of inhalant allergen sensitizations in Europe [J].

Burbach, G. J. ;

Heinzerling, L. M. ;

Edenharter, G. ;

Bachert, C. ;

Bindslev-Jensen, C. ;

Bonini, S. ;

Bousquet, J. ;

Bousquet-Rouanet, L. ;

Bousquet, P. J. ;

Bresciani, M. ;

Bruno, A. ;

Canonica, G. W. ;

Darsow, U. ;

Demoly, P. ;

Durham, S. ;

Fokkens, W. J. ;

Giavi, S. ;

Gjomarkaj, M. ;

Gramiccioni, C. ;

Haahtela, T. ;

Kowalski, M. L. ;

Magyar, P. ;

Murakozi, G. ;

Orosz, M. ;

Papadopoulos, N. G. ;

Rohnelt, C. ;

Stingl, G. ;

Todo-Bom, A. ;

von Mutius, E. ;

Wiesner, A. ;

Wohrl, S. ;

Zuberbier, T. .

ALLERGY, 2009, 64 (10) :1507-1515

← 1 2 3 4 5 6 7 8 9 10 →